Recombinant TcdB antibody

Catalog No. ABIN7566457

This Human Monoclonal antibody specifically detects TcdB in ELISA, Func and WB. It exhibits reactivity toward Clostridium difficile.

Quick Overview for Recombinant TcdB antibody (ABIN7566457)

Target: TcdB

Antibody Type: Recombinant Antibody

Reactivity: Clostridium difficile

Host: Human

Clonality: Monoclonal

Application: ELISA, Functional Studies (Func), Western Blotting (WB)

Clone: VIF090-A6

Product Details

Purpose: anti-TcdB (Clostridioides difficile extoxin), mAb (rec.) (VIF090-A6)

Characteristics:

Recombinant Antibody. Recognizes TcdB from Clostridioides difficile. Applications: ELISA, FUNC, WB. Clone: VIF090-A6. Isotype: Human IgG1. Formulation: Liquid. In PBS. Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.

Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.

Purification: Puified

Purity: >95 % (SDS-PAGE)

Immunogen: Recombinant TcdB (Clostridioides difficile, strain VPI10463) containing a C-terminal His-tag.

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: In PBS.

Handling Advice: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.Please handle under sterile conditions to avoid contamination.

Storage: 4 °C,-20 °C

Storage Comment:

Stable for at least 1 year after receipt when stored at -20°C.

Stable for at least 1 week when stored at +4°C.

Target Details

Target: TcdB

UniProt: Q189K3